nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—FLT4—polycystic ovary syndrome	0.694	1	CbGaD
Regorafenib—Sorafenib—FLT4—polycystic ovary syndrome	0.00503	1	CrCbGaD
Regorafenib—UGT1A1—urine—polycystic ovary syndrome	0.00283	0.0251	CbGeAlD
Regorafenib—DDR2—adrenal cortex—polycystic ovary syndrome	0.00177	0.0157	CbGeAlD
Regorafenib—DDR2—endometrium—polycystic ovary syndrome	0.00158	0.014	CbGeAlD
Regorafenib—CYP2C19—urine—polycystic ovary syndrome	0.00153	0.0136	CbGeAlD
Regorafenib—DDR2—uterus—polycystic ovary syndrome	0.00146	0.0129	CbGeAlD
Regorafenib—DDR2—pituitary gland—polycystic ovary syndrome	0.00143	0.0127	CbGeAlD
Regorafenib—DDR2—adipose tissue—polycystic ovary syndrome	0.00142	0.0126	CbGeAlD
Regorafenib—MAPK11—adipose tissue—polycystic ovary syndrome	0.00135	0.012	CbGeAlD
Regorafenib—FLT4—embryo—polycystic ovary syndrome	0.00132	0.0117	CbGeAlD
Regorafenib—DDR2—adrenal gland—polycystic ovary syndrome	0.00128	0.0113	CbGeAlD
Regorafenib—FRK—endocrine gland—polycystic ovary syndrome	0.00123	0.011	CbGeAlD
Regorafenib—MAPK11—adrenal gland—polycystic ovary syndrome	0.00121	0.0107	CbGeAlD
Regorafenib—EPHX2—adrenal cortex—polycystic ovary syndrome	0.0012	0.0106	CbGeAlD
Regorafenib—DDR2—female gonad—polycystic ovary syndrome	0.00119	0.0106	CbGeAlD
Regorafenib—CYP2C9—urine—polycystic ovary syndrome	0.00119	0.0105	CbGeAlD
Regorafenib—DDR2—vagina—polycystic ovary syndrome	0.00118	0.0105	CbGeAlD
Regorafenib—RET—embryo—polycystic ovary syndrome	0.00116	0.0103	CbGeAlD
Regorafenib—MAPK11—female gonad—polycystic ovary syndrome	0.00113	0.01	CbGeAlD
Regorafenib—BRAF—endometrium—polycystic ovary syndrome	0.00112	0.00991	CbGeAlD
Regorafenib—DDR2—endocrine gland—polycystic ovary syndrome	0.00111	0.00983	CbGeAlD
Regorafenib—FGFR2—embryo—polycystic ovary syndrome	0.0011	0.00979	CbGeAlD
Regorafenib—FLT4—adrenal cortex—polycystic ovary syndrome	0.00108	0.00956	CbGeAlD
Regorafenib—TEK—embryo—polycystic ovary syndrome	0.00106	0.00938	CbGeAlD
Regorafenib—BRAF—uterus—polycystic ovary syndrome	0.00103	0.00913	CbGeAlD
Regorafenib—FLT1—embryo—polycystic ovary syndrome	0.00102	0.00907	CbGeAlD
Regorafenib—RAF1—embryo—polycystic ovary syndrome	0.00102	0.00902	CbGeAlD
Regorafenib—BRAF—pituitary gland—polycystic ovary syndrome	0.00101	0.00897	CbGeAlD
Regorafenib—BRAF—adipose tissue—polycystic ovary syndrome	0.00101	0.00893	CbGeAlD
Regorafenib—EPHX2—uterus—polycystic ovary syndrome	0.000983	0.00873	CbGeAlD
Regorafenib—EPHX2—pituitary gland—polycystic ovary syndrome	0.000966	0.00857	CbGeAlD
Regorafenib—EPHX2—adipose tissue—polycystic ovary syndrome	0.000962	0.00853	CbGeAlD
Regorafenib—PDGFRA—embryo—polycystic ovary syndrome	0.000958	0.0085	CbGeAlD
Regorafenib—CYP3A4—urine—polycystic ovary syndrome	0.000906	0.00804	CbGeAlD
Regorafenib—BRAF—adrenal gland—polycystic ovary syndrome	0.000903	0.00801	CbGeAlD
Regorafenib—EPHA2—adrenal cortex—polycystic ovary syndrome	0.000889	0.00788	CbGeAlD
Regorafenib—FGFR1—uterus—polycystic ovary syndrome	0.000875	0.00776	CbGeAlD
Regorafenib—FLT4—adipose tissue—polycystic ovary syndrome	0.000867	0.0077	CbGeAlD
Regorafenib—TEK—adrenal cortex—polycystic ovary syndrome	0.000867	0.00769	CbGeAlD
Regorafenib—KDR—embryo—polycystic ovary syndrome	0.000865	0.00767	CbGeAlD
Regorafenib—EPHX2—adrenal gland—polycystic ovary syndrome	0.000863	0.00765	CbGeAlD
Regorafenib—FGFR1—pituitary gland—polycystic ovary syndrome	0.000859	0.00762	CbGeAlD
Regorafenib—FGFR1—adipose tissue—polycystic ovary syndrome	0.000856	0.00759	CbGeAlD
Regorafenib—BRAF—female gonad—polycystic ovary syndrome	0.000842	0.00747	CbGeAlD
Regorafenib—FLT1—adrenal cortex—polycystic ovary syndrome	0.000838	0.00744	CbGeAlD
Regorafenib—BRAF—vagina—polycystic ovary syndrome	0.000837	0.00742	CbGeAlD
Regorafenib—RAF1—adrenal cortex—polycystic ovary syndrome	0.000833	0.00739	CbGeAlD
Regorafenib—EPHX2—female gonad—polycystic ovary syndrome	0.000804	0.00714	CbGeAlD
Regorafenib—EPHX2—vagina—polycystic ovary syndrome	0.0008	0.00709	CbGeAlD
Regorafenib—EPHA2—endometrium—polycystic ovary syndrome	0.000793	0.00704	CbGeAlD
Regorafenib—FLT4—adrenal gland—polycystic ovary syndrome	0.000778	0.0069	CbGeAlD
Regorafenib—TEK—endometrium—polycystic ovary syndrome	0.000774	0.00687	CbGeAlD
Regorafenib—RET—pituitary gland—polycystic ovary syndrome	0.000769	0.00682	CbGeAlD
Regorafenib—FGFR1—adrenal gland—polycystic ovary syndrome	0.000768	0.00681	CbGeAlD
Regorafenib—KIT—embryo—polycystic ovary syndrome	0.000766	0.0068	CbGeAlD
Regorafenib—FLT1—endometrium—polycystic ovary syndrome	0.000748	0.00664	CbGeAlD
Regorafenib—PDGFRB—embryo—polycystic ovary syndrome	0.000748	0.00664	CbGeAlD
Regorafenib—RAF1—endometrium—polycystic ovary syndrome	0.000744	0.0066	CbGeAlD
Regorafenib—FGFR2—uterus—polycystic ovary syndrome	0.000744	0.0066	CbGeAlD
Regorafenib—FGFR2—adipose tissue—polycystic ovary syndrome	0.000728	0.00646	CbGeAlD
Regorafenib—FLT4—female gonad—polycystic ovary syndrome	0.000726	0.00644	CbGeAlD
Regorafenib—EPHA2—pituitary gland—polycystic ovary syndrome	0.000718	0.00637	CbGeAlD
Regorafenib—FGFR1—female gonad—polycystic ovary syndrome	0.000716	0.00635	CbGeAlD
Regorafenib—EPHA2—adipose tissue—polycystic ovary syndrome	0.000715	0.00634	CbGeAlD
Regorafenib—TEK—uterus—polycystic ovary syndrome	0.000713	0.00633	CbGeAlD
Regorafenib—FGFR1—vagina—polycystic ovary syndrome	0.000711	0.00631	CbGeAlD
Regorafenib—KDR—adrenal cortex—polycystic ovary syndrome	0.000708	0.00629	CbGeAlD
Regorafenib—TEK—pituitary gland—polycystic ovary syndrome	0.0007	0.00621	CbGeAlD
Regorafenib—TEK—adipose tissue—polycystic ovary syndrome	0.000698	0.00619	CbGeAlD
Regorafenib—FLT1—uterus—polycystic ovary syndrome	0.00069	0.00612	CbGeAlD
Regorafenib—RET—adrenal gland—polycystic ovary syndrome	0.000687	0.00609	CbGeAlD
Regorafenib—RAF1—uterus—polycystic ovary syndrome	0.000686	0.00608	CbGeAlD
Regorafenib—UGT1A9—endocrine gland—polycystic ovary syndrome	0.000684	0.00607	CbGeAlD
Regorafenib—FLT1—pituitary gland—polycystic ovary syndrome	0.000677	0.00601	CbGeAlD
Regorafenib—FLT4—endocrine gland—polycystic ovary syndrome	0.000675	0.00599	CbGeAlD
Regorafenib—FLT1—adipose tissue—polycystic ovary syndrome	0.000674	0.00598	CbGeAlD
Regorafenib—RAF1—pituitary gland—polycystic ovary syndrome	0.000673	0.00597	CbGeAlD
Regorafenib—RAF1—adipose tissue—polycystic ovary syndrome	0.000671	0.00595	CbGeAlD
Regorafenib—ABL1—embryo—polycystic ovary syndrome	0.000667	0.00592	CbGeAlD
Regorafenib—FGFR2—adrenal gland—polycystic ovary syndrome	0.000653	0.00579	CbGeAlD
Regorafenib—PDGFRA—uterus—polycystic ovary syndrome	0.000646	0.00573	CbGeAlD
Regorafenib—EPHA2—adrenal gland—polycystic ovary syndrome	0.000641	0.00569	CbGeAlD
Regorafenib—KDR—endometrium—polycystic ovary syndrome	0.000633	0.00561	CbGeAlD
Regorafenib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.000632	0.00561	CbGeAlD
Regorafenib—TEK—adrenal gland—polycystic ovary syndrome	0.000626	0.00555	CbGeAlD
Regorafenib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000613	0.00544	CbGeAlD
Regorafenib—FGFR2—female gonad—polycystic ovary syndrome	0.000609	0.0054	CbGeAlD
Regorafenib—FLT1—adrenal gland—polycystic ovary syndrome	0.000605	0.00537	CbGeAlD
Regorafenib—RAF1—adrenal gland—polycystic ovary syndrome	0.000601	0.00534	CbGeAlD
Regorafenib—EPHA2—female gonad—polycystic ovary syndrome	0.000598	0.00531	CbGeAlD
Regorafenib—RET—endocrine gland—polycystic ovary syndrome	0.000596	0.00528	CbGeAlD
Regorafenib—EPHA2—vagina—polycystic ovary syndrome	0.000594	0.00527	CbGeAlD
Regorafenib—TEK—female gonad—polycystic ovary syndrome	0.000583	0.00518	CbGeAlD
Regorafenib—KDR—uterus—polycystic ovary syndrome	0.000583	0.00517	CbGeAlD
Regorafenib—KDR—pituitary gland—polycystic ovary syndrome	0.000572	0.00508	CbGeAlD
Regorafenib—KDR—adipose tissue—polycystic ovary syndrome	0.00057	0.00506	CbGeAlD
Regorafenib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.000567	0.00503	CbGeAlD
Regorafenib—FGFR2—endocrine gland—polycystic ovary syndrome	0.000566	0.00502	CbGeAlD
Regorafenib—FLT1—female gonad—polycystic ovary syndrome	0.000564	0.005	CbGeAlD
Regorafenib—RAF1—female gonad—polycystic ovary syndrome	0.000561	0.00498	CbGeAlD
Regorafenib—FLT1—vagina—polycystic ovary syndrome	0.000561	0.00497	CbGeAlD
Regorafenib—KIT—endometrium—polycystic ovary syndrome	0.000561	0.00497	CbGeAlD
Regorafenib—RAF1—vagina—polycystic ovary syndrome	0.000557	0.00495	CbGeAlD
Regorafenib—EPHA2—endocrine gland—polycystic ovary syndrome	0.000556	0.00493	CbGeAlD
Regorafenib—PDGFRB—endometrium—polycystic ovary syndrome	0.000548	0.00486	CbGeAlD
Regorafenib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000547	0.00485	CbGeAlD
Regorafenib—TEK—endocrine gland—polycystic ovary syndrome	0.000543	0.00481	CbGeAlD
Regorafenib—PDGFRA—female gonad—polycystic ovary syndrome	0.000529	0.00469	CbGeAlD
Regorafenib—PDGFRA—vagina—polycystic ovary syndrome	0.000525	0.00466	CbGeAlD
Regorafenib—FLT1—endocrine gland—polycystic ovary syndrome	0.000525	0.00465	CbGeAlD
Regorafenib—RAF1—endocrine gland—polycystic ovary syndrome	0.000522	0.00463	CbGeAlD
Regorafenib—KIT—uterus—polycystic ovary syndrome	0.000517	0.00458	CbGeAlD
Regorafenib—KDR—adrenal gland—polycystic ovary syndrome	0.000511	0.00454	CbGeAlD
Regorafenib—KIT—pituitary gland—polycystic ovary syndrome	0.000507	0.0045	CbGeAlD
Regorafenib—KIT—adipose tissue—polycystic ovary syndrome	0.000505	0.00448	CbGeAlD
Regorafenib—PDGFRB—uterus—polycystic ovary syndrome	0.000505	0.00448	CbGeAlD
Regorafenib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000496	0.0044	CbGeAlD
Regorafenib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000493	0.00438	CbGeAlD
Regorafenib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.000492	0.00436	CbGeAlD
Regorafenib—ABL1—endometrium—polycystic ovary syndrome	0.000488	0.00433	CbGeAlD
Regorafenib—KDR—female gonad—polycystic ovary syndrome	0.000477	0.00423	CbGeAlD
Regorafenib—KDR—vagina—polycystic ovary syndrome	0.000474	0.0042	CbGeAlD
Regorafenib—UGT1A1—endocrine gland—polycystic ovary syndrome	0.000469	0.00416	CbGeAlD
Regorafenib—KIT—adrenal gland—polycystic ovary syndrome	0.000453	0.00402	CbGeAlD
Regorafenib—ABL1—uterus—polycystic ovary syndrome	0.00045	0.00399	CbGeAlD
Regorafenib—KDR—endocrine gland—polycystic ovary syndrome	0.000443	0.00393	CbGeAlD
Regorafenib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.000443	0.00393	CbGeAlD
Regorafenib—ABL1—pituitary gland—polycystic ovary syndrome	0.000442	0.00392	CbGeAlD
Regorafenib—ABL1—adipose tissue—polycystic ovary syndrome	0.00044	0.0039	CbGeAlD
Regorafenib—KIT—female gonad—polycystic ovary syndrome	0.000423	0.00375	CbGeAlD
Regorafenib—KIT—vagina—polycystic ovary syndrome	0.00042	0.00373	CbGeAlD
Regorafenib—PDGFRB—female gonad—polycystic ovary syndrome	0.000413	0.00366	CbGeAlD
Regorafenib—PDGFRB—vagina—polycystic ovary syndrome	0.00041	0.00364	CbGeAlD
Regorafenib—ABL1—adrenal gland—polycystic ovary syndrome	0.000395	0.0035	CbGeAlD
Regorafenib—KIT—endocrine gland—polycystic ovary syndrome	0.000393	0.00349	CbGeAlD
Regorafenib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000384	0.00341	CbGeAlD
Regorafenib—ABL1—female gonad—polycystic ovary syndrome	0.000368	0.00326	CbGeAlD
Regorafenib—ABL1—vagina—polycystic ovary syndrome	0.000366	0.00324	CbGeAlD
Regorafenib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000345	0.00306	CbGeAlD
Regorafenib—ABL1—endocrine gland—polycystic ovary syndrome	0.000342	0.00304	CbGeAlD
Regorafenib—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000318	0.00282	CbGeAlD
Regorafenib—CYP2C8—endometrium—polycystic ovary syndrome	0.000317	0.00281	CbGeAlD
Regorafenib—ABCG2—endometrium—polycystic ovary syndrome	0.000308	0.00273	CbGeAlD
Regorafenib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000286	0.00254	CbGeAlD
Regorafenib—ABCG2—uterus—polycystic ovary syndrome	0.000284	0.00252	CbGeAlD
Regorafenib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000279	0.00247	CbGeAlD
Regorafenib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000277	0.00246	CbGeAlD
Regorafenib—CYP2C19—vagina—polycystic ovary syndrome	0.000272	0.00241	CbGeAlD
Regorafenib—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000254	0.00226	CbGeAlD
Regorafenib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000249	0.00221	CbGeAlD
Regorafenib—CYP2C8—vagina—polycystic ovary syndrome	0.000237	0.0021	CbGeAlD
Regorafenib—ABCG2—female gonad—polycystic ovary syndrome	0.000232	0.00206	CbGeAlD
Regorafenib—ABCG2—vagina—polycystic ovary syndrome	0.000231	0.00205	CbGeAlD
Regorafenib—CYP2B6—adrenal gland—polycystic ovary syndrome	0.00023	0.00204	CbGeAlD
Regorafenib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000222	0.00197	CbGeAlD
Regorafenib—CYP2B6—vagina—polycystic ovary syndrome	0.000213	0.00189	CbGeAlD
Regorafenib—ABCB1—embryo—polycystic ovary syndrome	0.000207	0.00184	CbGeAlD
Regorafenib—CYP2B6—endocrine gland—polycystic ovary syndrome	0.000199	0.00177	CbGeAlD
Regorafenib—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000197	0.00175	CbGeAlD
Regorafenib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00017	0.00151	CbGeAlD
Regorafenib—ABCB1—endometrium—polycystic ovary syndrome	0.000152	0.00135	CbGeAlD
Regorafenib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00015	0.00133	CbGeAlD
Regorafenib—ABCB1—uterus—polycystic ovary syndrome	0.00014	0.00124	CbGeAlD
Regorafenib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000137	0.00122	CbGeAlD
Regorafenib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000137	0.00121	CbGeAlD
Regorafenib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000123	0.00109	CbGeAlD
Regorafenib—ABCB1—female gonad—polycystic ovary syndrome	0.000114	0.00101	CbGeAlD
Regorafenib—ABCB1—vagina—polycystic ovary syndrome	0.000114	0.00101	CbGeAlD
Regorafenib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000106	0.000944	CbGeAlD
Regorafenib—PDGFRB—Disease—INS—polycystic ovary syndrome	4.31e-06	2.29e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.3e-06	2.28e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	4.29e-06	2.28e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IRS2—polycystic ovary syndrome	4.24e-06	2.25e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	4.23e-06	2.25e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—LEP—polycystic ovary syndrome	4.22e-06	2.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRG1—polycystic ovary syndrome	4.22e-06	2.24e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.19e-06	2.22e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	4.19e-06	2.22e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—polycystic ovary syndrome	4.18e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	4.18e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	4.18e-06	2.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT2—polycystic ovary syndrome	4.17e-06	2.21e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—MTHFR—polycystic ovary syndrome	4.16e-06	2.21e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—MTHFR—polycystic ovary syndrome	4.16e-06	2.21e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—LEP—polycystic ovary syndrome	4.14e-06	2.2e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—polycystic ovary syndrome	4.11e-06	2.18e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IRS1—polycystic ovary syndrome	4.1e-06	2.18e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	4.08e-06	2.17e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IRS1—polycystic ovary syndrome	4.06e-06	2.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT2—polycystic ovary syndrome	4.02e-06	2.13e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—polycystic ovary syndrome	4.02e-06	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.02e-06	2.13e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.02e-06	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IRS1—polycystic ovary syndrome	4.01e-06	2.13e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	4.01e-06	2.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IRS2—polycystic ovary syndrome	4.01e-06	2.13e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	3.99e-06	2.12e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	3.99e-06	2.12e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.99e-06	2.12e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	3.96e-06	2.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—SERPINE1—polycystic ovary syndrome	3.96e-06	2.1e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	3.96e-06	2.1e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—POMC—polycystic ovary syndrome	3.95e-06	2.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—BCL2—polycystic ovary syndrome	3.94e-06	2.09e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.93e-06	2.09e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—LEP—polycystic ovary syndrome	3.93e-06	2.09e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	3.93e-06	2.08e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—INS—polycystic ovary syndrome	3.93e-06	2.08e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—LEP—polycystic ovary syndrome	3.92e-06	2.08e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—POMC—polycystic ovary syndrome	3.91e-06	2.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—polycystic ovary syndrome	3.9e-06	2.07e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	3.9e-06	2.07e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—INS—polycystic ovary syndrome	3.89e-06	2.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—polycystic ovary syndrome	3.89e-06	2.06e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	3.87e-06	2.05e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	3.87e-06	2.05e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—INS—polycystic ovary syndrome	3.84e-06	2.04e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—BCL2—polycystic ovary syndrome	3.84e-06	2.04e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.83e-06	2.03e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF1—polycystic ovary syndrome	3.8e-06	2.01e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT2—polycystic ovary syndrome	3.8e-06	2.01e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	3.79e-06	2.01e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	3.77e-06	2e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—TH—polycystic ovary syndrome	3.76e-06	2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.76e-06	2e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF1—polycystic ovary syndrome	3.76e-06	2e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT2—polycystic ovary syndrome	3.76e-06	1.99e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.76e-06	1.99e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	3.74e-06	1.98e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	3.73e-06	1.98e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	3.73e-06	1.98e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT2—polycystic ovary syndrome	3.71e-06	1.97e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	3.7e-06	1.96e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	3.68e-06	1.95e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—SLC2A4—polycystic ovary syndrome	3.66e-06	1.94e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	3.64e-06	1.93e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	3.64e-06	1.93e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—POMC—polycystic ovary syndrome	3.63e-06	1.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	3.61e-06	1.92e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.61e-06	1.91e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—INS—polycystic ovary syndrome	3.61e-06	1.91e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	3.58e-06	1.9e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.57e-06	1.9e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	3.56e-06	1.89e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.56e-06	1.89e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	3.55e-06	1.89e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	3.54e-06	1.88e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	3.54e-06	1.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—polycystic ovary syndrome	3.54e-06	1.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	3.53e-06	1.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—SERPINE1—polycystic ovary syndrome	3.53e-06	1.87e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	3.53e-06	1.87e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	3.53e-06	1.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—BCL2—polycystic ovary syndrome	3.51e-06	1.86e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.51e-06	1.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.51e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	3.5e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	3.5e-06	1.86e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	3.5e-06	1.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.49e-06	1.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.48e-06	1.85e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	3.45e-06	1.83e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	3.44e-06	1.83e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	3.42e-06	1.82e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	3.42e-06	1.82e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	3.41e-06	1.81e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	3.4e-06	1.8e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—POMC—polycystic ovary syndrome	3.38e-06	1.79e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	3.37e-06	1.79e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PPARG—polycystic ovary syndrome	3.37e-06	1.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	3.37e-06	1.79e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—INS—polycystic ovary syndrome	3.36e-06	1.78e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	3.35e-06	1.78e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	3.34e-06	1.77e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	3.33e-06	1.76e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—POMC—polycystic ovary syndrome	3.33e-06	1.76e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.31e-06	1.76e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—INS—polycystic ovary syndrome	3.31e-06	1.76e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—INS—polycystic ovary syndrome	3.31e-06	1.76e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	3.29e-06	1.74e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	3.27e-06	1.73e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	3.26e-06	1.73e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.25e-06	1.73e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.25e-06	1.72e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.25e-06	1.72e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.25e-06	1.72e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	3.24e-06	1.72e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	3.24e-06	1.72e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	3.22e-06	1.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.22e-06	1.71e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	3.21e-06	1.7e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.2e-06	1.7e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	3.19e-06	1.69e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	3.17e-06	1.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	3.15e-06	1.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—LEP—polycystic ovary syndrome	3.15e-06	1.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—polycystic ovary syndrome	3.12e-06	1.66e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	3.1e-06	1.64e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.09e-06	1.64e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.08e-06	1.63e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	3.07e-06	1.63e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.05e-06	1.62e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	3.05e-06	1.62e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	3.04e-06	1.61e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	3.02e-06	1.6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	3.02e-06	1.6e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—polycystic ovary syndrome	3e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	3e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	2.93e-06	1.55e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	2.92e-06	1.55e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	2.92e-06	1.55e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	2.92e-06	1.55e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.89e-06	1.53e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	2.86e-06	1.52e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TH—polycystic ovary syndrome	2.85e-06	1.51e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	2.82e-06	1.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.81e-06	1.49e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—INS—polycystic ovary syndrome	2.81e-06	1.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TH—polycystic ovary syndrome	2.78e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	2.78e-06	1.47e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.77e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	2.77e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.76e-06	1.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—POMC—polycystic ovary syndrome	2.71e-06	1.44e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.7e-06	1.43e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.69e-06	1.43e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—INS—polycystic ovary syndrome	2.69e-06	1.43e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—polycystic ovary syndrome	2.65e-06	1.41e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.61e-06	1.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.6e-06	1.38e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	2.6e-06	1.38e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	2.6e-06	1.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.6e-06	1.38e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TH—polycystic ovary syndrome	2.59e-06	1.38e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	2.59e-06	1.37e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.54e-06	1.35e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	2.52e-06	1.34e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.48e-06	1.32e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	2.48e-06	1.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.47e-06	1.31e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.46e-06	1.3e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—polycystic ovary syndrome	2.44e-06	1.29e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—polycystic ovary syndrome	2.43e-06	1.29e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.4e-06	1.27e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—polycystic ovary syndrome	2.39e-06	1.27e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	2.37e-06	1.26e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	2.35e-06	1.25e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.33e-06	1.23e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	2.32e-06	1.23e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.28e-06	1.21e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—polycystic ovary syndrome	2.27e-06	1.2e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.27e-06	1.2e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	2.27e-06	1.2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—polycystic ovary syndrome	2.25e-06	1.19e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.24e-06	1.19e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.24e-06	1.19e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.21e-06	1.17e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—polycystic ovary syndrome	2.21e-06	1.17e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	2.19e-06	1.16e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.16e-06	1.15e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.15e-06	1.14e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.13e-06	1.13e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.12e-06	1.13e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	2.12e-06	1.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.12e-06	1.12e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.11e-06	1.12e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	2.1e-06	1.11e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.1e-06	1.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—polycystic ovary syndrome	2.1e-06	1.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—polycystic ovary syndrome	2.09e-06	1.11e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	2.07e-06	1.1e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—INS—polycystic ovary syndrome	2.06e-06	1.09e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.05e-06	1.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	2.04e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	2.02e-06	1.07e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.01e-06	1.07e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—polycystic ovary syndrome	2e-06	1.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.99e-06	1.06e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—polycystic ovary syndrome	1.99e-06	1.05e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.98e-06	1.05e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	1.96e-06	1.04e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	1.91e-06	1.01e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.91e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.91e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—polycystic ovary syndrome	1.88e-06	9.99e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—polycystic ovary syndrome	1.82e-06	9.65e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	1.78e-06	9.46e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	1.78e-06	9.42e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	1.75e-06	9.29e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	1.74e-06	9.24e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—polycystic ovary syndrome	1.72e-06	9.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.71e-06	9.07e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.7e-06	9.02e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	9.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—polycystic ovary syndrome	1.68e-06	8.91e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.66e-06	8.83e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.59e-06	8.41e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—polycystic ovary syndrome	1.58e-06	8.36e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.56e-06	8.3e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.56e-06	8.29e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.56e-06	8.25e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.55e-06	8.21e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	1.55e-06	8.21e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.53e-06	8.1e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.52e-06	8.05e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—polycystic ovary syndrome	1.47e-06	7.79e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	1.46e-06	7.77e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	1.45e-06	7.67e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	1.43e-06	7.56e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—INS—polycystic ovary syndrome	1.42e-06	7.52e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.4e-06	7.41e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.33e-06	7.06e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	1.32e-06	7e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.26e-06	6.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—polycystic ovary syndrome	1.18e-06	6.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.18e-06	6.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	9.54e-07	5.06e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	9.4e-07	4.99e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	9.35e-07	4.96e-06	CbGpPWpGaD
